|[January 03, 2013]
Dr. Reddy's Announces the Launch of Finasteride Tablets
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories (NYSE: RDY) announced today that is has
launched Finasteride Tablets (1 mg), a bioequivalent generic version of
Propecia® (Finasteride) Tablets in the US market on January 02, 2013.
Dr. Reddy's ANDA for Finasteride 1 mg Tablets has been awarded a 180-day
period of marketing exclusivity in the U.S. on 2 Jan, 2013.
The Propecia® Tablets brand has U.S. sales of approximately $136 Million
MAT for the most recent twelve months ending in October 2012 according
to IMS Health*.
Dr. Reddy's Finasteride Tablets 1 mg is available in bottle counts of 30
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve kown and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary
Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars,
differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain
management, anti-infective and pediatrics. Major markets include India,
USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand. For more information, log on to: www.drreddys.com.
Propecia® is a registered trademark of Merck Sharp (News - Alert) & Dohme Corp., a
subsidiary of Merck & Co., Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT October 2012
[ Back To TMCnet.com's Homepage ]